United States Food and Drug Administration (USFDA) has completed Post-marketing Adverse Drug Experience (PADE) inspection at Jubilant Pharmova’s stepdown wholly owned subsidiary -- Jubilant Cadista Pharmaceuticals Inc, USA. The inspection closed with no observations.
The above inspection concluded with zero observations, reaffirming Jubilant commitment to maintaining the highest standards of quality, safety, and compliance.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
